US court rejects Teva’s patent-infringement claims on Copaxone
- Is WTO working for India and China?
- Traditional vs Western: Which attire is more popular among men in India?
- Govt to boost trade ties with Asean: Dharmendra Pradhan
- India, Australia and Japan bat for rules-based order in Indo-Pacific
- MDR rates revised to cut losses of acquirer banks, says RBI deputy governor B.P. Kanungo
Bengaluru: Teva Pharmaceutical Industries Ltd said on Monday a US court rejected four of the Israel-based drugmaker’s claims of patent infringement on its top-selling multiple sclerosis treatment.
The rejection comes four months after US patent officials invalidated three patents on its drug Copaxone, in response to challenges by pharmaceutical company Mylan NV, which has been trying to market a generic version of the drug.
All asserted claims of Teva were invalid, the US District Court Of Delaware said in a ruling on Monday.
The patents, which expire in 2030, cover a 40-milligram injection of Copaxone that patients administer three times a week.
Generics may only be sold after a drug’s patents expire or are invalidated through litigation.
However, Teva said it planned to appeal the decision.
US-listed shares of Teva were down almost 9% in after-hours trading, while Mylan’s shares edged up marginally. Reuters